Wisconsin Alumni Research Foundation

Therapeutics & Vaccines
Therapeutics Vaccines
Natural Antibiotic to Treat Clostridium Infection and More
WARF: P140428US02

Inventors: Timothy Bugni, Thomas Wyche, Douglas Braun, Jeff Piotrowski, Nasia Safdar

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing ecteinamycin, a compound that may be more potent than drugs currently used to treat serious bacterial infections.
Bacterial resistance to antibiotics is an escalating problem, especially in hospital settings. The Centers for Disease Control recently identified Clostridium difficile as posing an “urgent” health threat, highlighting the need for new and effective therapeutics.

C. difficile is the most common cause of nosocomial infectious diarrhea. The bacteria sicken half a million people each year and 20 percent of patients get sick again following treatment.
The Invention
UW–Madison researchers have identified a potential new antibiotic to treat infections caused by C. difficile, Staphylococcus and other drug-resistant strains. The compound is a natural product called ecteinamycin. It was discovered and isolated from a sea squirt bacterium (Actinomadura). Preliminary data suggests ecteinamycin is potent, selective and able to protect cells against bacterial toxins.
  • Novel antibiotic to fight Gram-positive/negative bacteria, including C. difficile, methicillin-resistant S. aureus and vancomycin-resistant Enterococcus
Key Benefits
  • Potential new weapon against dangerous and drug-resistant bacteria
  • May be superior to available antibiotics
Stage of Development
Ecteinamycin has demonstrated potent in vitro activity against C. difficile. It showed greater potency than vancomycin (the “last resort” drug) against several different Gram-positive bacteria.
Additional Information
For More Information About the Inventors
For current licensing status, please contact Rafael Diaz at [javascript protected email address] or 608-960-9847